CollPlant Biotechnologies Ltd.

CollPlant Biotechnologies Ltd. is an Israeli regenerative and aesthetic medicine company headquartered in Rehovot, Israel. The company's core business revolves around developing innovative technologies and products for tissue regeneration and organ manufacturing. Its mission is to discover, develop, and deliver collagen technology and regenerative medicine products to improve and prolong lives. CollPlant's foundational technology utilizes proprietary plant-derived recombinant human collagen (rhCollagen), which is bioidentical to human collagen and produced using genetically engineered tobacco plants.

The company leverages its rhCollagen platform to develop a pipeline of products for medical aesthetics and 3D bioprinting of tissues and organs. Key product areas include regenerative breast implants, dermal and soft tissue fillers, and BioInks for 3D bioprinting. CollPlant also offers tissue repair products for orthobiologics and advanced wound care, such as Vergenix STR for tendinopathy and Vergenix FG for wound care.

Under the leadership of CEO Yehiel Tal, CollPlant has recently focused on expanding its commercial reach and product development. In March 2026, the company launched a redesigned corporate website to enhance transparency and accessibility for stakeholders. CollPlant has a development and commercialization agreement with AbbVie for dermal and soft tissue fillers, which triggered a $2 million payment in February 2025. The company is also expanding the distribution of its Vergenix STR product in Europe and Asia and optimizing its regenerative breast implants. Furthermore, CollPlant launched BioFlex, an rhCollagen-based kit for Digital Light Processing (DLP) 3D bioprinting applications, in February 2026 and has secured patents for its photocurable dermal filler technology in South Korea and Japan.